companydata.dkUnibio USA ApS: Financial statements 2024
CVR: 38179845
Unibio USA ApS (CVR 38179845) has filed annual accounts for 2024. In 2024, the company reported a net result of DKK -26,000 compared with DKK -17,000 the year before. Equity amounted to DKK 45,000. The solvency ratio was 72.6%.
- Profit/Loss
- -26,000 kr.
- Equity
- 45,000 kr.
- Total Assets
- 62,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | - | -26 t. | 45 t. | - |
| 2023 | - | - | -17 t. | 71 t. | - |
| 2022 | - | -18 t. | -34 t. | 88 t. | 0 |
| 2021 | - | -15 t. | -12 t. | 72 t. | 0 |
| 2020 | - | -14 t. | -11 t. | 8 t. | 0 |
How creditworthy is Unibio USA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2024
Unibio USA ApS has published its annual report for 2023. The net result was DKK -17,000.
As of January 24, 2024, Søren Olrik Eklund is registered as director of Unibio USA ApS.
As of January 24, 2024, David Richard Henstrom is registered as adm. dir. of Unibio USA ApS.
As of January 24, 2024, Jakob Brix Christensen has stepped down as director of Unibio USA ApS.
As of January 23, 2024, Søren Olrik Eklund has stepped down as adm. dir. of Unibio USA ApS.
About Unibio USA ApS
Unibio USA ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Søren Olrik Eklund and David Richard Henstrom. The company is owned by UNIBIO A/S. In 2025, the company reported a net result of DKK -20,000 compared with DKK -26,000 the year before. Equity amounted to DKK 25,000.